Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence of Loxoprofen Sodium Patches (FB3002 vs Loxonin) in Healthy Chinese Volunteers
NCT06510413Phase 1Not yet recruiting
- Sponsor
- Frontier Biotechnologies Inc.
- Start
- Jul 2024
- Primary completion
- Aug 2024
- Modality
- Small Molecules
01
Overview
Phase 1, randomised, open-label trial of loxoprofen in osteoarthritis (OA) and myalgia (2 arms), sponsored by Frontier Biotechnologies Inc. Primary endpoints: Maximum Plasma Concentration, Area Under the Curve from time 0 to the last measurable concentration and 1 more. Planned start Jul 2024; status: not yet recruiting.
02
Drugs
loxoprofen
03
Conditions
osteoarthritis (OA)myalgia
Beyond the preview
Go deeper on NCT06510413.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06510413.